MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer

Journal of Proteomics

Volumn 91, Issue , 2013, Pages 500-514

  Pallua, Johannes Dominikus ^a,b   Schaefer, Georg ^b,c   Seifarth, Christof ^b   Becker, Michael ^d   Meding, Stephan ^e,f   Rauser, Sandra ^e   Walch, Axel ^e   Handler, Michael ^g   Netzer, Michael ^g   Popovscaia, Marina ^g   Osl, Melanie ^g   Baumgartner, Christian ^g   Lindner, Herbert ^b   Kremser, Leopold ^b   Sarg, Bettina ^b   Bartsch, Georg ^b   Huck, Christian W ^a   Bonn, Günther K ^a   Klocker, Helmut ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^d BRUKER DALTONIK GMBH   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Biliverdin reductase; Heme metabolism; Mass spectrometry tissue imaging; Prostate cancer; Tissue biomarker

Indexed keywords

BILIVERDIN REDUCTASE B; BIOLOGICAL MARKER; OXIDOREDUCTASE; PROSTATE SPECIFIC ANTIGEN; TISSUE EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SIZE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FROZEN SECTION; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION MASSPECTROMETRY TISSUE IMAGING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEOMICS; STROMA; TANDEM MASS SPECTROMETRY; TISSUE SECTION;

ALPHA METHYLACYL COA RACEMASE; AMACR; BILIVERDIN REDUCTASE; BLVR; GLEASON SCORE (SUM OF THE TWO MOST ABUNDANT TUMOR GLEASON PATTERNS); GS; HE; HEMATOXILIN-EOSINE; HEME METABOLISM; IHC; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY TISSUE IMAGING; P53-RELATED PROTEIN P63; P63; PATHOLOGICAL TUMOR STAGE; PCA; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN; PSA; PT; REGION OF INTEREST; ROI; TISSUE BIOMARKER; TISSUE MICRO ARRAY.; TMA;

AGED; AREA UNDER CURVE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84884126478     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.08.003     Document Type: Article

References (89)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Bosetti C., Bertuccio P., Chatenoud L., Negri E., La Vecchia C., Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 2011, 60:1-15.
4. Boyle P., Severi G., Giles G.G. The epidemiology of prostate cancer. Urol Clin North Am 2003, 30:209-217.
5. Epstein J.I. An update of the Gleason grading system. J Urol 2010, 183:433-440.
6. Helpap B., Egevad L. Modified Gleason grading. An updated review. Histol Histopathol 2009, 24:661-666.
7. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol 2008, 30:190-198.
8. Klotz L. Cancer overdiagnosis and overtreatment. Curr Opin Urol 2012, 22:203-209.
9. Bangma C.H., Roemeling S., Schroder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007, 25:3-9.
10. Lippi G., Montagnana M., Guidi G.C., Plebani M. Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?. Ann Med 2009, 41:480-489.
11. Loeb S., Catalona W.J. Prostate-specific antigen in clinical practice. Cancer Lett 2007, 249:30-39.
12. Ito K. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives. Int J Urol 2009, 16:458-464.
13. Lin K., Lipsitz R., Miller T., Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 149:192-199.
14. Stephan C., Jung K., Lein M., Diamandis E.P. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007, 43:1918-1926.
15. Epstein J.I., Feng Z., Trock B.J., Pierorazio P.M. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012, 61:1019-1024.
16. Corcoran N.M., Hovens C.M., Hong M.K., Pedersen J., Casey R.G., Connolly S., et al. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 2012, 109:660-664.
17. Colleselli D., Pelzer A.E., Steiner E., Ongarello S., Schaefer G., Bartsch G., et al. Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range. Prostate Cancer Prostatic Dis 2010, 13:182-185.
18. Bul M., Schroder F.H. Screening for prostate cancer - the controversy continues, but can it be resolved?. Acta Oncol 2011, 50(Suppl. 1):4-11.
19. Getzenberg R.H., Carter H.B. Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer. Asian J Androl 2012, 14:347-348.
20. Madu C.O., Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010, 1:150-177.
21. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001, 40:231-238.
22. Cornett D.S., Reyzer M.L., Chaurand P., Caprioli R.M. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods 2007, 4:828-833.
23. Walch A., Rauser S., Deininger S.O., Hofler H. MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem Cell Biol 2008, 130:421-434.
24. Cazares L.H., Troyer D.A., Wang B., Drake R.R., Semmes O.J. MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem 2011, 401:17-27.
25. Balluff B., Schone C., Hofler H., Walch A. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem Cell Biol 2011, 136:227-244.
26. Bateson H., Saleem S., Loadman P.M., Sutton C.W. Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research. J Pharmacol Toxicol Methods 2011, 64:197-206.
27. Schwamborn K., Caprioli R.M. Molecular imaging by mass spectrometry - looking beyond classical histology. Nat Rev Cancer 2010, 10:639-646.
28. Seeley E.H., Caprioli R.M. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol 2011, 29:136-143.
29. Shanta S.R., Zhou L.H., Park Y.S., Kim Y.H., Kim Y., Kim K.P. Binary matrix for MALDI imaging mass spectrometry of phospholipids in both ion modes. Anal Chem 2011, 83:1252-1259.
30. Sugiura Y., Setou M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 2010, 5:31-43.
31. McDonnell L.A., Corthals G.L., Willems S.M., van Remoortere A., van Zeijl R.J., Deelder A.M. Peptide and protein imaging mass spectrometry in cancer research. J Proteomics 2010, 73:1921-1944.
32. Rauser S., Marquardt C., Balluff B., Deininger S.O., Albers C., Belau E., et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010, 9:1854-1863.
33. Cornett D.S., Mobley J.A., Dias E.C., Andersson M., Arteaga C.L., Sanders M.E., et al. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics 2006, 5:1975-1983.
34. Schwartz S.A., Weil R.J., Thompson R.C., Shyr Y., Moore J.H., Toms S.A., et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
35. El Ayed M., Bonnel D., Longuespee R., Castelier C., Franck J., Vergara D., et al. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit 2010, 16:BR233-BR245.
36. Lemaire R., Menguellet S.A., Stauber J., Marchaudon V., Lucot J.P., Collinet P., et al. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 2007, 6:4127-4134.
37. Gustafsson J.O., Oehler M.K., Ruszkiewicz A., McColl S.R., Hoffmann P. MALDI imaging mass spectrometry (MALDI-IMS) - application of spatial proteomics for ovarian cancer classification and diagnosis. Int J Mol Sci 2011, 12:773-794.
38. Meding S., Balluff B., Elsner M., Schone C., Rauser S., Nitsche U., et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol 2012, 228:459-470.
39. Balluff B., Rauser S., Meding S., Elsner M., Schone C., Feuchtinger A., et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011, 179:2720-2729.
40. Elsner M., Rauser S., Maier S., Schone C., Balluff B., Meding S., et al. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J Proteomics 2012, 75:4693-4704.
41. Djidja M.C., Claude E., Snel M.F., Francese S., Scriven P., Carolan V., et al. Novel molecular tumour classification using MALDI-mass spectrometry imaging of tissue micro-array. Anal Bioanal Chem 2010, 397:587-601.
42. Cazares L.H., Troyer D., Mendrinos S., Lance R.A., Nyalwidhe J.O., Beydoun H.A., et al. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 2009, 15:5541-5551.
43. Schwamborn K., Krieg R.C., Reska M., Jakse G., Knuechel R., Wellmann A. Identifying prostate carcinoma by MALDI-Imaging. Int J Mol Med 2007, 20:155-159.
44. Steurer S., Borkowski C., Odinga S., Buchholz M., Koop C., Huland H., et al. MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. Int J Cancer 2013, 133:920-928.
45. Bonnel D., Longuespee R., Franck J., Roudbaraki M., Gosset P., Day R., et al. Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Anal Bioanal Chem 2011, 401:149-165.
46. Oberaigner W., Siebert U., Horninger W., Klocker H., Bektic J., Schafer G., et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012, 57:57-62.
47. Bartsch G., Horninger W., Klocker H., Pelzer A., Bektic J., Oberaigner W., et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008, 101:809-816.
48. Oberaigner W., Horninger W., Klocker H., Schonitzer D., Stuhlinger W., Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 2006, 164:376-384.
49. Kloss-Brandstatter A., Schafer G., Erhart G., Huttenhofer A., Coassin S., Seifarth C., et al. Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am J Hum Genet 2010, 87:802-812.
50. Deininger S.O., Becker M., Suckau D. Tutorial: multivariate statistical treatment of imaging data for clinical biomarker discovery. Methods Mol Biol 2010, 656:385-403.
51. Handler M., Pallua J., Schäfer G., Netzer M., Osl M., Seger M., et al. A workflow for preprocessing and proteomic biomarker identification on mass-spectrometry data. Proc 8th IASTED Int Conf on Biomedical Engineering, Innsbruck, Austria (Biomed'2011) 2011, 181-187.
52. Plant C., Baumgartner C., Tilg B. Feature selection on proteomic data for identifying biomarker candicates 2009, [Europe]. Office EP (Ed.).
53. Zhu J., Hastie T. Classification of gene microarrays by penalized logistic regression. Biostatistics 2004, 5:427-443.
54. Li X., Gentleman R., Lu X., Shi Q., Iglehart J., Harries L., et al. SELDI-TOF mass spectrometry protein data. Bioinformatics and computational biology solutions using R and bioconductor - Statistics for Biology and Health 2005, 91-109. Springer, New York. M. Gail, K. Krickeberg, J. Samet, A. Tsiatis, W. Wong, R. Gentleman (Eds.).
55. Skvortsov S., Schafer G., Stasyk T., Fuchsberger C., Bonn G.K., Bartsch G., et al. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res 2011, 10:259-268.
56. Bu H., Bormann S., Schafer G., Horninger W., Massoner P., Neeb A., et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 2011, 71:575-587.
57. Detre S., Saclani Jotti G., Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995, 48:876-878.
58. Groseclose M.R., Massion P.P., Chaurand P., Caprioli R.M. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008, 8:3715-3724.
59. Franck J., Longuespee R., Wisztorski M., Van Remoortere A., Van Zeijl R., Deelder A., et al. MALDI mass spectrometry imaging of proteins exceeding 30,000 daltons. Med Sci Monit 2010, 16:BR293-BR299.
60. Mainini V., Bovo G., Chinello C., Gianazza E., Grasso M., Cattoretti G., et al. Detection of high molecular weight proteins by MALDI imaging mass spectrometry. Mol Biosyst 2013, 9:1101-1107.
61. Leinweber B.D., Tsaprailis G., Monks T.J., Lau S.S. Improved MALDI-TOF imaging yields increased protein signals at high molecular mass. J Am Soc Mass Spectrom 2009, 20:89-95.
62. van Remoortere A., van Zeijl R.J., van den Oever N., Franck J., Longuespee R., Wisztorski M., et al. MALDI imaging and profiling MS of higher mass proteins from tissue. J Am Soc Mass Spectrom 2010, 21:1922-1929.
63. Schaefer G., Mosquera J.M., Ramoner R., Park K., Romanel A., Steiner E., et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis 2013, 16:132-138.
64. Pereira P.J., Macedo-Ribeiro S., Parraga A., Perez-Luque R., Cunningham O., Darcy K., et al. Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol 2001, 8:215-220.
65. Yamaguchi T., Komoda Y., Nakajima H. Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem 1994, 269:24343-24348.
66. Wegiel B., Otterbein L.E. Go green: the anti-inflammatory effects of biliverdin reductase. Front Pharmacol 2012, 3:47.
67. Baranano D.E., Rao M., Ferris C.D., Snyder S.H. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 2002, 99:16093-16098.
68. Jansen T., Hortmann M., Oelze M., Opitz B., Steven S., Schell R., et al. Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. J Mol Cell Cardiol 2011, 49:186-195.
69. Kim S.Y., Kang H.T., Choi H.R., Park S.C. Biliverdin reductase A in the prevention of cellular senescence against oxidative stress. Exp Mol Med 2011, 43:15-23.
70. Kapitulnik J., Maines M.D. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 2009, 30:129-137.
71. Wegiel B., Baty C.J., Gallo D., Csizmadia E., Scott J.R., Akhavan A., et al. Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem 2009, 284:21369-21378.
72. Lerner-Marmarosh N., Miralem T., Gibbs P.E., Maines M.D. Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc Natl Acad Sci U S A 2008, 105:6870-6875.
73. Lerner-Marmarosh N., Shen J., Torno M.D., Kravets A., Hu Z., Maines M.D. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Natl Acad Sci U S A 2005, 102:7109-7114.
74. Gibbs P.E., Tudor C., Maines M.D. Biliverdin reductase: more than a namesake - the reductase, its peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front Pharmacol 2012, 3:31.
75. Ahmad Z., Salim M., Maines M.D. Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress. J Biol Chem 2002, 277:9226-9232.
76. Kravets A., Hu Z., Miralem T., Torno M.D., Maines M.D. Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J Biol Chem 2004, 279:19916-19923.
77. Maines M.D., Mayer R.D., Erturk E., Huang T.J., Disantagnese A. The oxidoreductase, biliverdin reductase, is induced in human renal carcinoma-pH and cofactor-specific increase in activity. J Urol 1999, 162:1467-1472.
78. Melle C., Ernst G., Scheibner O., Kaufmann R., Schimmel B., Bleul A., et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res 2007, 6:306-315.
79. Patterson A.D., Maurhofer O., Beyoglu D., Lanz C., Krausz K.W., Pabst T., et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011, 71:6590-6600.
80. Zhang J., Wang K., Liu S.S., Dai L., Zhang J.Y. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 2011, 10:2863-2872.
81. Hellman K., Alaiya A.A., Becker S., Lomnytska M., Schedvins K., Steinberg W., et al. Differential tissue-specific protein markers of vaginal carcinoma. Br J Cancer 2009, 100:1303-1314.
82. Yu K.H., Barry C.G., Austin D., Busch C.M., Sangar V., Rustgi A.K., et al. Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res 2009, 8:1565-1576.
83. Monge M., Doll A., Colas E., Gil-Moreno A., Castellvi J., Garcia A., et al. Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 2009, 8:4676-4684.
84. Agren R., Bordel S., Mardinoglu A., Pornputtapong N., Nookaew I., Nielsen J. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol 2012, 8:e1002518.
85. Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 2012, 3:55.
86. Florczyk U., Golda S., Zieba A., Cisowski J., Jozkowicz A., Dulak J. Overexpression of biliverdin reductase enhances resistance to chemotherapeutics. Cancer Lett 2011, 300:40-47.
87. Maines M.D. Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings. Curr Drug Targets 2010, 11:1586-1594.
88. Barone E., Di Domenico F., Cenini G., Sultana R., Cini C., Preziosi P., et al. Biliverdin reductase - a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta 1812, 2011:480-487.
89. Liu Y., Liu J., Tetzlaff W., Paty D.W., Cynader M.S. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic Biol Med 2006, 40:960-967.